Pfizer | HKSAN

Screenshot 2021-06-24 at 18.22_edited.jpg

Hybrid Exhibition
1 - 3 October 2021

Foyer, William Mong M.W. Building,
LKS Faculty of Medicine,
The University of Hong Kong

Gold Sponsor

AF 360 is a multifaceted initiative bringing together both patients and healthcare professionals to address the unmet needs of atrial fibrillation and improve patient outcomes.

By coming together, we can reduce the number of preventable strokes, and make a real difference to the lives of patients with atrial fibrillation.

#1 NOAC Globally

ELIQUIS™ (apixaban) is a factor Xa inhibitor, a kind of novel oral anticoagulant. It is also frequently known as non-vitamin K antagonist oral anticoagulant (NOAC).

Learn more about Eliquis™ >

*ELIQUIS™ accounted for more patient treatment days prescribed around the world than any other NOAC. Patient treatment days prescribed estimated based on IQVIA MIDAS 2019 Q2 Sell-In/Sell-Out data.

Reference

1.IQVIA MIDAS, Days of Treatment volume a calculation of IQVIA Standard Units, Q2 2019, divided by recommended administration of each NOAC within 24hrs. [apixaban BID, dabigatran BID, edoxaban QD, rivaroxaban QD]2.ELIQUIS™ (apixaban) 2.5 mg & 5 mg Prescribing Information. Pfizer Corporation Hong Kong Limited. Version: July 2019.

ELIQUIS™ is the only NOAC to demonstrate superior risk reductions for BOTH stroke/systemic embolism and major bleeding vs warfarin

1,2

Comparison with warfarin >

Reference
1. Granger CB, et al. N Engl J Med 2011;365:981-992. 2.Ruff CT, et al. Lancet 2014;383:955-962.

Treating every stage of VTE with ELIQUIS™
Start & stay with Eliquis for the treatment and prevention of recurrent DVT/PE

VTE management with Eliquis™ >

Reference
1.ELIQUIS™ (apixaban) 2.5 mg & 5 mg Prescribing Information. Pfizer Corporation Hong Kong Limited. Version: July 2019.

Contact us

Enquiry Email: HKMedinfo.Pfizer@Pfizer.com
General Line: +852 2811 9711
Website: www.Pfizer.com.hk